Overview
Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE. The specific drugs discussed include anifrolumab [AZN], atacicept [MKGAY], Benlysta / belimumab [GSK], Benlysta SC [GSK], Lupuzor / rigerimod, Luveniq / voclosporin, Orencia / abatacept [BMY], Rituxan / rituximab [RHHBF] and Xeljanz/Xeljanz XR / tofacitinib [PFE]. The two interviews were combined into a single report.